FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to a dry powder pharmaceutical composition for pulmonary delivery for treating lymphangioleiomyomatosis in a human in need thereof. Composition contains micronised rapamycin, carrier particles, wherein carrier comprises a mixture of two different lactose carriers, and one or more optional excipients selected from a phospholipid and a metal salt of a fatty acid. Micronised rapamycin has mass median aerodynamic diameter (MMDA) from 1 to 5 microns. Rapamycin is the only therapeutic substance in the composition. Dry powder of rapamycin is delivered by inhaler. Also described is a method of treating lymphangioleiomyomatosis by inhalation of a dry powdered rapamycin composition.
EFFECT: composition according to the invention provides high local concentration of rapamycin in lung tissue with an inhalation route.
18 cl, 8 dwg, 9 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RAPAMYCIN-CONTAINING COMPOSITION ADMINISTERED BY INHALATION FOR TREATING AGE-RELATED DISEASES | 2015 |
|
RU2718583C2 |
| INHALATION DOSAGE FORM OF RAPAMYCIN FOR TREATING PULMONARY HYPERTENSION | 2015 |
|
RU2732908C2 |
| PEGYLATED LIPID NANOPARTICLE WITH A BIOACTIVE LIPOPHILIC COMPOUND | 2016 |
|
RU2737893C2 |
| BARE METAL STENT WITH MEDICATION-RELEASING RESERVOIRS | 2011 |
|
RU2573107C2 |
| RAPAMICIN-RELEASING STENT | 2010 |
|
RU2563429C2 |
| STENT WITH DOUBLE DRUG RELEASE | 2010 |
|
RU2552086C2 |
| PHARMACEUTICAL COMPOSITIONS | 1996 |
|
RU2159107C2 |
| TREATING AND PREVENTING HIV INFECTION | 2010 |
|
RU2569058C2 |
| COMPOSITIONS FOR DRUG INTRODUCTION | 2009 |
|
RU2554814C2 |
| COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS | 2009 |
|
RU2522977C2 |
